SAVICELL Corp
company.status.inactiveCIK 1498380fmd_0RXZRSH7TRZ12YYE5G9RWNDPHMManufacturing · In Vitro & In Vivo Diagnostic SubstancesTemplate: Standard
Coverage: Jan 01, 2009 to Sep 30, 2019, 39 periods
| Line item | FY2009 | FY2010 | FY2011 | FY2012 | FY2013 | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 |
|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | – | – | 0 | 4 | 0 | 0 | 2 | 1 | 1 | 3 |
| Total operating expenses | – | 0 | 0 | 4 | 1 | 1 | 2 | 2 | 2 | 3 |
| Operating income | – | (0) | (0) | (4) | (1) | – | – | – | – | – |
| Interest expense | – | 0 | 0 | 0 | 0 | (0) | 0 | 0 | 0 | 0 |
| Other non-operating income (expense) | – | – | (0) | (4) | (1) | – | – | – | – | – |
| Income tax expense | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Net income from continuing operations | – | – | – | – | – | – | – | (2) | (2) | (4) |
| Net income | (0) | (0) | (0) | (4) | (1) | (1) | (2) | (2) | (2) | (3) |
| Net income to common shareholders | – | – | – | – | – | – | – | – | – | (4) |